New hope for stomach cancer: experimental combo targets advanced disease
NCT ID NCT07361991
First seen Jan 24, 2026 · Last updated May 02, 2026 · Updated 17 times
Summary
This study is for people with advanced stomach cancer that has gotten worse after their first treatment. It tests an experimental drug called IBI363, which helps the immune system fight cancer, combined with other drugs. The goal is to see if this combination is safe and can shrink tumors or slow the disease. About 50 adults aged 18 to 75 will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.